Japan Statin Treatment Against Recurrent Stroke (J-STARS)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Although hyperlipidemia is not always the risk factor of stroke, inhibition of
3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase can decrease the incidence of stroke
in the patient with ischemic heart disease. The neuroprotective mechanism beyond cholesterol
lowering should be expected to attenuate inflammation and atherosclerosis. The present study
hypothesizes if pravastatin prevents recurrent stroke in the ischemic stroke patients with
safety.
Phase:
Phase 3
Details
Lead Sponsor:
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan Translational Research Informatics Center, Kobe, Hyogo, Japan
Collaborators:
Hiroshima University Ministry of Health, Labour and Welfare, Japan